Ayumi Sato, Takeshi Fukumoto, Ai Yoshioka, Chikako Nishigori
{"title":"Implications of interleukin-17 in psoriatic lesions as Koebner phenomenon caused by recurrent occupational burns.","authors":"Ayumi Sato, Takeshi Fukumoto, Ai Yoshioka, Chikako Nishigori","doi":"10.4081/dr.2022.9567","DOIUrl":"https://doi.org/10.4081/dr.2022.9567","url":null,"abstract":"<p><p>The Koebner phenomenon (KP) is the emergence of new lesions in an uninvolved skin area caused by different types of stimulations, including mechanical stress, chemical stress, trauma, or injury. KP affects patients with certain skin diseases and is frequently observed in patients with psoriasis. We report the case of a 43-year-old obese male welder who developed psoriatic lesions only in areas of repeated burns due to his occupation. He was repeatedly exposed to mild burns in his anterior neck and the periorbital region as he was welding without shield protection. Subsequently, erythema appeared in the same region. Skin appearance and skin biopsy suggested psoriasis vulgaris (PV), and immunohistochemical analysis of anti-interleukin (IL)-17, a crucial element in the development of PV, showed the positivestained cells. The anti-IL-17 staining was prominent around the thickened epidermis as psoriatic lesions. IL-17 produced by T helper 17 cells stimulates keratinized cells and promotes chemokine secretion involved in neutrophil migration. Our case showed that patients, even without a history of PV, may have a risk of developing KP and PV via the enhanced production of IL- 17 locally in the repeated burn area. No recurrence of skin symptoms was observed when the patient used a fully defensive shield during welding.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 2","pages":"9567"},"PeriodicalIF":1.1,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/59/dr-15-2-9567.PMC10312102.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10122329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lorry Aitkens, Joel Byrne, Charay Jennings-Dover, Kathryn Anne Potter
{"title":"A case of squamous cell carcinoma arising in a giant porokeratosis previously diagnosed as psoriasis.","authors":"Lorry Aitkens, Joel Byrne, Charay Jennings-Dover, Kathryn Anne Potter","doi":"10.4081/dr.2023.9634","DOIUrl":"https://doi.org/10.4081/dr.2023.9634","url":null,"abstract":"<p><p>Porokeratosis (PK) is a disorder of keratinization with a clinical presentation of an atrophic center surrounded by a hyperkeratotic border. Lesions of porokeratosis carry a risk of malignant transformation with giant porokeratosis (GPK) being a high-risk variant. We report a case in which a single, large, erythematous, scaly plaque in an immunocompromised patient showed initial histopathological features consistent with psoriasis and subsequent histological features consistent with GPK. This plaque underwent malignant transformation to squamous cell carcinoma on three occasions. This case highlights that specimens taken from central portions of porokeratosis may resemble a variety of dermatoses histologically, including psoriasis, resulting in misdiagnosis as seen in our patient. When a patient presents with a diagnosis previously made that isn't responding to therapy as expected, repeat biopsy is appropriate.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 2","pages":"9634"},"PeriodicalIF":1.1,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/de/dr-15-2-9634.PMC10312101.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10122334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Certolizumab to treat hidradenitis suppurativa.","authors":"Asem Shadid, Saud Alobaida, Yousef Binamer","doi":"10.4081/dr.2022.9566","DOIUrl":"https://doi.org/10.4081/dr.2022.9566","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that affects apocrine gland-bearing skin. The management of HS with biologics has expanded significantly over the past few years. Certolizumab pegol is a pegylated (polyethylene glycol) antigen-binding fragment of a recombinant humanized anti-TNF-α monoclonal antibody, which is approved for psoriasis, rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. In recent years many reports have been merging on the use of certolizumab in treating hidradenitis suppurativa. The electronic database MEDLINE was searched through PubMed in February 2022 using the following search terms: Certolizumab \"[All Fields] OR\" certolizumab pegol\"[All Fields] AND \"Hidradenitis suppurativa\"[ All Fields]. The search revealed that certolizumab was used in 6 case reports to treat HS with a total of 7 patients. We can conclude that there are few cases in the literature discussing the use of certolizumab in HS, all of which, show a good and promising response with no reported side effects.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 2","pages":"9566"},"PeriodicalIF":1.1,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/4c/dr-15-2-9566.PMC10312105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dermatology ReportsPub Date : 2023-06-06eCollection Date: 2023-09-12DOI: 10.4081/dr.2023.9642
Gianmaria Viglizzo, Astrid Herzum, Lodovica Gariazzo, Ehab Garibeh, Corrado Occella
{"title":"Pediatric spitzoid lesions of the ear: a single-center experience and review of the literature.","authors":"Gianmaria Viglizzo, Astrid Herzum, Lodovica Gariazzo, Ehab Garibeh, Corrado Occella","doi":"10.4081/dr.2023.9642","DOIUrl":"https://doi.org/10.4081/dr.2023.9642","url":null,"abstract":"<p><p>Spitzoid lesions are challenging melanocytic lesions comprising benign, intermediate, and malignant lesions. In this study, we aimed to analyze the diagnostic accuracy of clinical and dermatoscopical evaluations of pediatric spitzoid ear lesions. We collected and analyzed, clinically, dermatoscopically, and histologically, pediatric spitzoid ear lesions. We also conducted a systematic review of the literature. At the Pediatric Hospital Gaslini, excision and histopathological evaluation were performed on eight cases: 87.5% of the lesions were consistent with Spitz nevus (SN), and 12.5% with atypical Spitz tumor (AST). Notably, multiple (≥2) dermatoscopical irregularities were present in 5 of 7 SN (71%), yet none were found in AST (0%, 0/1) (Fisher's exact test, P=0.375). From systematic research in the literature, 9 patients were included in this review. At histology, 88.9% were SN and 11% AST. Remarkably, also in the literature, multiple dermatoscopical irregularities were present in most SN (75%, 6/8), but not in the identified AST (0%, 0/1) (P=0.3333). We present a monocentric study on pediatric spitzoid ear lesions. Importantly, dermatoscopical irregularities were not significantly associated with AST, neither in our series nor in the reviewed literature (respectively P=0.375 and P=0.3333), supporting the fact that relying only on the dermatoscopical aspect of spitzoid lesions is not accurate enough for the special site of the ear, where dermatoscopy could actually be misleading.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9642"},"PeriodicalIF":1.1,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/e0/dr-15-3-9642.PMC10518529.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41110733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dermatology ReportsPub Date : 2023-06-06eCollection Date: 2023-09-12DOI: 10.4081/dr.2023.9547
Gianmaria Viglizzo, Astrid Herzum, Lodovica Gariazzo, Camilla Olcese, Corrado Occella
{"title":"Childhood vitiligo developing after COVID-19 infection.","authors":"Gianmaria Viglizzo, Astrid Herzum, Lodovica Gariazzo, Camilla Olcese, Corrado Occella","doi":"10.4081/dr.2023.9547","DOIUrl":"https://doi.org/10.4081/dr.2023.9547","url":null,"abstract":"<p><p>Both COVID-19 and vaccinations against it have been related to immune cutaneous manifestations. Here, we present a case of childhood vitiligo, developed after a COVID-19 infection.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9547"},"PeriodicalIF":1.1,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/e7/dr-15-3-9547.PMC10518528.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41118154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dermatology ReportsPub Date : 2023-06-06eCollection Date: 2023-09-12DOI: 10.4081/dr.2023.9676
Benedetta Sonego, Enrico Zelin, Iris Zalaudek, Nicola di Meo
{"title":"Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature.","authors":"Benedetta Sonego, Enrico Zelin, Iris Zalaudek, Nicola di Meo","doi":"10.4081/dr.2023.9676","DOIUrl":"10.4081/dr.2023.9676","url":null,"abstract":"<p><p>Bullous pemphigoid (BP) is an autoimmune disease with a chronic relapsing course, predominantly affecting elderly people. Drugs are one of the possible triggers. A class of antidiabetic drugs often associated with the development of BP are inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins), while less known is the association with glucagon-like-peptide-1 receptor agonists. We describe a case of BP caused by dulaglutide and summarize the other few cases described in the literature. As a class of drugs widely used in clinical practice, it is important to know about this possible adverse event.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9676"},"PeriodicalIF":1.1,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/70/dr-15-3-9676.PMC10563024.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dermatology ReportsPub Date : 2023-06-06eCollection Date: 2023-09-12DOI: 10.4081/dr.2023.9584
Gianmaria Viglizzo, Astrid Herzum, Lodovica Gariazzo, Corrado Occella
{"title":"Facial pruritic skin rash in a Nigerian boy with atopic dermatitis.","authors":"Gianmaria Viglizzo, Astrid Herzum, Lodovica Gariazzo, Corrado Occella","doi":"10.4081/dr.2023.9584","DOIUrl":"10.4081/dr.2023.9584","url":null,"abstract":"<p><p>We present the case of a 4-year-old boy with annular, pruritic macules on the face who did not respond to the application of topical immunosuppressive therapy for atopic dermatitis. In this case report, we emphasize how pruritic annular macules that are not responsive to immunosuppressants should always be suspected of being tinea incognita.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9584"},"PeriodicalIF":1.1,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/10/dr-15-3-9584.PMC10563027.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dermatology ReportsPub Date : 2023-06-05eCollection Date: 2023-09-12DOI: 10.4081/dr.2023.9677
Novita, Khairuddin Djawad
{"title":"Modified H-plasty in large basal cell carcinoma defect reconstruction on the forehead.","authors":"Novita, Khairuddin Djawad","doi":"10.4081/dr.2023.9677","DOIUrl":"https://doi.org/10.4081/dr.2023.9677","url":null,"abstract":"<p><p>Basal cell carcinoma (BCC) is the most common malignancy worldwide. Surgical removal is considered the gold standard treatment. However, large defects following excisional surgery can pose a significant challenge for reconstruction, especially in cases where primary closure is not possible. In these cases, skin flaps may be used. Most traditional skin flaps are limited by design to take advantage of only one region of relative skin excess. This paper reports a case of a large forehead defect following BCC excision that was successfully reconstructed by a modified Hplasty involving a U-plasty and rotation-advancement flap. Maintenance of aesthetics without impaired function is the aim of closure defects with combined flaps.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9677"},"PeriodicalIF":1.1,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/b0/dr-15-3-9677.PMC10563029.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A case of perifolliculitis capitis abscedens et suffodiens and acne conglobata treated effectively with a TNF-α inhibitor","authors":"Shinpei Miura, Kanako Tsunoda, H. Amano","doi":"10.4081/dr.2023.9699","DOIUrl":"https://doi.org/10.4081/dr.2023.9699","url":null,"abstract":"Perifolliculitis capitis abscedens et suffodiens (PCAS) and acne conglobate (AC) are often treated with isotretinoin and tumor necrosis factor alpha (TNF-α) inhibitors in Europe and the United States. Treatment with these drugs is uncommon in Asia, and alternative treatment options are limited. In this paper, we report the case of a Japanese patient who presented with PCAS and AC and was treated successfully with adalimumab.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"1 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70147943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}